首页> 外文期刊>Clinical, Cosmetic and Investigational Dermatology >Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice
【24h】

Botulinum toxin type A treatment to the upper face: retrospective analysis of daily practice

机译:A型肉毒毒素治疗的上脸:日常实践的回顾性分析

获取原文
           

摘要

Background: Botulinum toxin type A treatment has been used for over 20 years to enhance the appearance of the face. There are several commercially available botulinum toxin type A products used in aesthetic clinical practice. The aim of this retrospective analysis was to compare the clinical efficacy of the most commonly used botulinum toxin type A preparations in daily practice.Methods: Physicians from 21 centers in Germany completed questionnaires based on an inspection of subject files for subjects 18 years of age or over who had received at least two, but not more than three, consecutive treatments with incobotulinumtoxinA, onabotulinumtoxinA, or abobotulinumtoxinA within a 12-month period in the previous 2 years. Data on subject and physician satisfaction, treatment intervals, dosages, and safety were collected from 1256 subjects.Results: There were no statistically significant differences between incobotulinumtoxinA and onabotulinumtoxinA with respect to physician and subject satisfaction, dosages, and adverse effects experienced. Both botulinum toxin type A preparations were well tolerated and effective in the treatment of upper facial lines. Due to low treatment numbers, abobotulinumtoxinA was not included in the statistical analysis.Conclusion: The results of this retrospective analysis confirm the results of prospective clinical trials by demonstrating that, in daily practice, incobotulinumtoxinA and onabotulinumtoxinA are used at a 1:1 dose ratio and display comparable efficacy and safety.
机译:背景:A型肉毒杆菌毒素治疗已使用20多年,可改善面部外观。在审美临床实践中有几种可商购的A型肉毒毒素产品。这项回顾性分析的目的是比较日常实践中最常用的A型肉毒杆菌毒素制剂的临床疗效。方法:来自德国21个中心的医师根据对18岁或18岁以上受试者的受试者档案的检查完成了问卷谁在过去2年中的12个月内接受了至少两次但不超过三次连续的incobotulinumtoxinA,onabotulinumtoxinA或abobotulinumtoxinA治疗。收集了来自1256名受试者的受试者和医师满意度,治疗间隔,剂量和安全性的数据。两种A型肉毒毒素制剂均具有良好的耐受性,并且可以有效地治疗上面部。由于治疗次数少,因此统计分析中不包括肉毒杆菌毒素。结论:这项回顾性分析的结果证实了日常使用incobotulinum毒素A和ona肉毒杆菌毒素A的剂量比,从而证实了前瞻性临床试验的结果。并显示出可比的功效和安全性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号